Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof

Definitions

• the present invention relates to pharmaceutical compositions active as analgesics as well as to methods for alleviating the symptoms of pain.
• one aspect of the invention provides a pharmaceutical composition for oral or rectal administration comprising as active agents: a) Hydroxyzine in free form or in pharmaceutically acceptable salt form, and b) one or more non-steroidal anti-inflammatory agent and / or acetaminophen.
• Active agent a) is known and can be prepared e.g. as described in USP 2,899,436.
• any of a wide variety of non-steroidal, anti-inflammatory agents may be used as active agents b).
• Useful materials include aspirin; sodium 5- (4-chlorobenzoyl) -1, 4-dimethyl-1H-pyrrole-2-acetate dihydrate (generically referred to as zomepirac sodium); 4-hydroxy-2-methyl-N- (2-pyridyl) -2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (generic name Piroxicam); 2 ', 4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid (generic name Diflunisal); 1-isopropyl-7-methyl-4-phenyl-2 (1H) -quinazolinone (generic name Proquazone); and arylacetic acid or aryl propionic acid compounds including the non-toxic therapeutically acceptable salts thereof, eg the sodium, potassium or calcium salts.
• Examples of useful arylacetic acid and arylpropionic acid compounds include 2- (p-isobutylphenyl) propionic acid (generic name Ibuprofen); alpha-methyl-4- (2-thienylcarbonyl) benzene acetic acid (generic name Suprofen); 4,5-diphenyl-2oxazole propionic acid (generic name oxaprozin); rac-6-chloro-alpha-methylcarbazole-2-acetic acid (generic name Carprofen); 2- (3-phenyloxyphenyl) propionic acid, particularly the calcium salt dihydrate thereof (these compounds being referred to generically as Fenoprofen and Fenoprofen calcium); 2- (6-methoxy-2-naphthyl) propionic acid (generic name Naproxen; the generic name of the sodium salt is Naproxen sodium); 4- (1,3-dihydro-1-oxo-2H-isoindol-2-
• active agents a) and b) are the sole active analgesic constituents in the pharmaceutical combinations according to the invention.
• Preferred as active agent b) is a non-steroidal anti-inflammatory agent in particular one or more of those listed above.
• compositions according to the invention suitably contain pharmaceutically acceptable carriers or diluents which are admixed with the active agents and are conventional and well known in the art.
• compositions of this invention may be adapted for oral administration and administration through the rectum.
• Forms suitable for oral administration are for example tablets, dispersible powders, granules, capsules, syrups, elixirs or suspensions.
• Compositions for oral use contain one or more conventional adjuvants, such as sweetening agents flavoring agents, coloring agents and preserving agents, in order to provide an elegant and palatable preparation.
• Tablets may contain the active ingredients in admixture with conventional pharmaceutically acceptable excipients, eg inert diluents, such as calcium carbonate, sodium carbonate, lactose, and talc, granulating and disintegrating agents, eg starch and aligninic acid, binding agents, eg starch gelatin and acacia , and lubricating agents, eg magnesium stearate, stearic acid and talc.
• excipients eg inert diluents, such as calcium carbonate, sodium carbonate, lactose, and talc
• granulating and disintegrating agents eg starch and aligninic acid, binding agents, eg starch gelatin and acacia
• lubricating agents eg magnesium stearate, stearic acid and talc.
• the tablets may be uncoated or coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained
• suspensions, syrups and elixirs may contain the active ingredients in admixture with any of the conventional excipients utilized in the preparation of such compositions, eg suspending agents such as methyl-cellulose, tragacanth and sodium alginate; wetting agents such as lecithin, polyoxyethylene stearate and polyoxyethylene sorbitan monooleate; and preservatives such as ethyl p-hydroxybenzoate.
• suspending agents such as methyl-cellulose, tragacanth and sodium alginate
• wetting agents such as lecithin, polyoxyethylene stearate and polyoxyethylene sorbitan monooleate
• preservatives such as ethyl p-hydroxybenzoate.
• Capsules may contain the active ingredients alone or admixed with an inert solid diluent, eg calcium carbonate, calcium phosphate and kaolin.
• These pharmaceutical compositions may contain up to about 90% of the active ingredients in combination with
• compositions are put up in unit dosage form particularly in unit dosage form for oral administration.
• Such forms may contain the active ingredients separately, eg in separate layers in a layer or mantle tablet or in split capsules.
• Oral administration is preferred.
• a further aspect of the invention concerns a process for the production of a pharmaceutical composition as stated above which comprises formulating active agent a) with active agent b) as stated above and optionally putting up the preparation in unit dosage form.
• a clinical test was conducted involving subjects who were outpatients undergoing the surgical removal of impacted teeth. After surgery was completed, the patients were given one dose of a medication and a questionnaire. They were asked to take the medication when their postoperative pain reached moderate to severe intensity.
• the patients were given a placebo, 600 milligrams of acetaminophen, 100 milligrams of Hydroxyzine pamoate, or a mixture of 100 milligrams of Hydroxyzine pamoate and 600 milligrams of acetaminophen.
• Pain intensity difference scores were derived by subtracting the pain level at each hour after ingestion from the intensity at the time of initial administration. Hence if the patient's pain was judged to be "moderate” (value of 2) at the start of the test and the patient judged his pain to be "slight” at hours one, two, three and four (assigned value of 1 ), the pain intensity difference score would be 4, that is 2 minus 1 or plus 1 at each of the four hourly measuring points. Pain relief scores for each pain estimate were assigned according to patient's hourly estimate of relief. Accordingly, if the patient recorded a little relief at hour one into the test (a score of 1) and some relief at hour two (a sccre of 2) and a Tot of relief at hours three and four (score 3 for each hour) his pain relief score would be 9.
• test scores are therefore the sum of five readings rather than 4 readings as in the above test
• the patients were given 100 mg of Hydroxyzine pamoate, 400 mg ibuprofen or a mixture of 100 mg hydroxyzine pamoate with 400 mg of ibuprofen.
• test scores are therefore the sum of seven readings rather than four readings as in the first test.
• the patients were given a placebo, 200 milligrams of fenoprofen calcium, 100mg of hydroxyzine pamoate or a mixture of 100mg of hydroxyzine pamoate with 200 mg of fenoprofen calcium.
• the test data are shown in Table 3 below.
• the invention further provides a method of alleviating the Symptoms of pain in a subject in need of such treatment, which method comprises concomitantly administering to said subject an effective amount of an active agent a) and an active agent b) as stated above.
• the therapeutic dose differs with the kind of pharmaceutic process, severity of the condition, administration schedule and other known factors when co-administration is invisaged, and doses typically continued until the condition causing the pain is ameliorated.
• the NSAID or acetaminophen will be co-administered with a pain relieving potentiating effective amount of hydroxyzine (or its salts), in a total combined pain relieving effective amount, in doses given 3 to 6 times a day as needed to relieve pain.
• at least 25 mg of hydroxyzine and its salts will be administered per dose, preferably at least 50 mg and typically at least 70 mg.
• a dose for each administration of hydroxyzine and its salts may range from 25 mg to 120 mg, more usually 25 mg to 100 mg, preferably 50 mg to 100 mg, and typically 70 mg to 100mg.
• the amount of the non-steroid anti-inflammatory agent to be co-administered with the hydroxyzine will vary depending mainly on the particular agent desired. In general, it is desirable to employ at least an amount of the NSAID (or acetaminophen when it may be used) that would by itself be minimally effective clinically in the adult human to produce analgesia.
• the particularly preferred NSAIDs are those classed as arylacetic and arylpropionic acids (and the pharmaceutically acceptable salts) including, for example, ibuprofen, oxaprozin, carprofen, fenoprofen or fenoprofen calcium, naproxin or naproxin sodium, indoprofen, ketoprofen, flurbiprofen and tolmetin or tolmetin .
• the NSAIDs proquazone, zomepirac, piroxicam and diflunisal.
• Suitable doses for acetaminiphen are from 200-1,300 mg, preferably 300-650 mg, leading to the same weight ratios with hydroxyzine (25 to 100 mg ranks and 50 to 100 mg ranks) as indicated for aspirin in Table I.
• weight ratio ranges of hydroxyzine for the hydroxyzine dose ranges of 25 to 120 mg and 70 to 100 mg, to the dose ranges for NSAIDs given in Table I may be readily calculated from the dose ranges given in Column A of Table I for the particular NSAID (as well as from the above information for acetaminophen), and such weight ratio ranges are also deemed disclosed in. It will be evident that the weight ratio ranges of hydroxyzine to the NSAID or acetaminophen as indicated above may be used to formulate pharmaceutical compositions in accordance with the invention, provided that a NSAID or acetaminophen pain relieving potentiating effective amount of hydroxyzine is included. Conveniently the active agents will be administered in fixed combinations having eg the individual dosages outlined above and in unit dosage form.
• They can be administered e.g. in sustained release form or in divided doses 2 to 4 times a day or as indicated by the condition to be treated e.g. 3 to 6 times as needed to relieve pain.
• the active agents a) and b) can also be administered e.g. in the indicated dosages individually and concomitantly.
• the invention therefore also provides a pack comprising separately a plurality of dosage units of each of active agents a) and b) together with instructions for their concomitant administration.
• compositions for use in the invention are illustrative of compositions for use in the invention.
• a No. 1 capsule containing the ingredients indicated below may be prepared by conventional techniques and administered at a dose of 1 or 2 capsules 4 to 6 times a day to relieve pain.
• Example B A tablet containing the ingredients indicated below may be prepared by conventional techniques and administered at a dose of 1 or 2 tablets 3 to 5 times a day to relieve pain.
• Example B Using a Single dose tablet containing 75 mg of hydroxyzine hydrochloride and formulated as in Example B (75 mg of proquazone), and administered in a cl inica l test as described above, indicated after 6 hours a clear potentiation of the pain rel ieving effects of proquazone by the hydroxyzine.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Chemical And Physical Treatments For Wood And The Like (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (2)

Applications Claiming Priority (1)

Publications (1)

Family

ID=23779713

Family Applications (1)

Country Status (14)

Cited By (2)

Families Citing this family (4)

• 1983
  • 1983-12-07 HU HU84281A patent/HU196126B/hu not_active IP Right Cessation
  • 1983-12-07 JP JP84500121A patent/JPS60500016A/ja active Pending
  • 1983-12-07 NZ NZ206504A patent/NZ206504A/en unknown
  • 1983-12-07 PT PT77793A patent/PT77793B/pt not_active IP Right Cessation
  • 1983-12-07 WO PCT/EP1983/000326 patent/WO1984002273A1/de not_active Ceased
  • 1983-12-07 AU AU23352/84A patent/AU570937B2/en not_active Ceased
  • 1983-12-08 IL IL70407A patent/IL70407A/xx unknown
  • 1983-12-09 GR GR73209A patent/GR79475B/el unknown
  • 1983-12-09 DE DE8383810581T patent/DE3380165D1/de not_active Expired
  • 1983-12-09 ZA ZA839196A patent/ZA839196B/xx unknown
  • 1983-12-09 CA CA000442921A patent/CA1237077A/en not_active Expired
  • 1983-12-09 AT AT83810581T patent/ATE44461T1/de not_active IP Right Cessation
  • 1983-12-09 EP EP83810581A patent/EP0111456B1/en not_active Expired
• 1984
  • 1984-08-01 DK DK374584A patent/DK374584D0/da not_active Application Discontinuation

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events